JP7372982B2 - Ａｏａｈを過剰発現する遺伝子組換え間葉系幹細胞及びその使用 - Google Patents

Ａｏａｈを過剰発現する遺伝子組換え間葉系幹細胞及びその使用 Download PDF

Info

Publication number
JP7372982B2
JP7372982B2 JP2021547607A JP2021547607A JP7372982B2 JP 7372982 B2 JP7372982 B2 JP 7372982B2 JP 2021547607 A JP2021547607 A JP 2021547607A JP 2021547607 A JP2021547607 A JP 2021547607A JP 7372982 B2 JP7372982 B2 JP 7372982B2
Authority
JP
Japan
Prior art keywords
msc
aoah
polypeptide
promoter
angpt1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513379A (ja
JP2022513379A5 (enExample
Inventor
マイケル キャラハン
シャーリー エイチ ジェイ メイ
ヤン ワン
マリア フロリアン
ケイトリン ロウ
チャン ジャン リー
Original Assignee
オタワ ホスピタル リサーチ インスティチュート
ユナイテッド セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オタワ ホスピタル リサーチ インスティチュート, ユナイテッド セラピューティクス コーポレイション filed Critical オタワ ホスピタル リサーチ インスティチュート
Publication of JP2022513379A publication Critical patent/JP2022513379A/ja
Publication of JP2022513379A5 publication Critical patent/JP2022513379A5/ja
Application granted granted Critical
Publication of JP7372982B2 publication Critical patent/JP7372982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021547607A 2018-10-29 2019-10-29 Ａｏａｈを過剰発現する遺伝子組換え間葉系幹細胞及びその使用 Active JP7372982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
US62/752,000 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (3)

Publication Number Publication Date
JP2022513379A JP2022513379A (ja) 2022-02-07
JP2022513379A5 JP2022513379A5 (enExample) 2022-08-05
JP7372982B2 true JP7372982B2 (ja) 2023-11-01

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547607A Active JP7372982B2 (ja) 2018-10-29 2019-10-29 Ａｏａｈを過剰発現する遺伝子組換え間葉系幹細胞及びその使用

Country Status (10)

Country Link
US (1) US20220010281A1 (enExample)
EP (1) EP3874029B1 (enExample)
JP (1) JP7372982B2 (enExample)
KR (1) KR20210086662A (enExample)
CN (1) CN113166729A (enExample)
AU (1) AU2019370629A1 (enExample)
ES (1) ES2962812T3 (enExample)
IL (1) IL282820A (enExample)
SG (1) SG11202103509RA (enExample)
WO (1) WO2020087160A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021360131A1 (en) * 2020-10-16 2023-05-25 Ottawa Hospital Research Institute Cell-based therapy for viral diseases
CN116570711A (zh) * 2022-12-21 2023-08-11 上海交通大学医学院附属第九人民医院 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528566A (ja) 2008-07-21 2011-11-24 コンプジェン リミティッド アンジオポエチン由来ペプチド
JP2011529957A (ja) 2008-08-04 2011-12-15 セレリックス エスエー 間葉系幹細胞の使用
JP2014533961A (ja) 2011-11-24 2014-12-18 フンダシオ インスティトゥート ディンベスティガシオ ビオメディカ デ ベルビテージ（イディベル） 改変された幹細胞およびその治療的な使用
JP2016537416A (ja) 2013-11-01 2016-12-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 脳マラリアを治療するためのアンギオポエチンに基づいた介入
JP2017502690A (ja) 2013-12-20 2017-01-26 ノバルティス アーゲー 調節可能キメラ抗原受容体
JP2017520583A (ja) 2014-06-30 2017-07-27 ティジェニクス エス．エー．ユー． 全身性炎症反応症候群の治療のための間葉系間質細胞
JP2018521122A (ja) 2015-06-12 2018-08-02 レンティジェン・テクノロジー・インコーポレイテッドＬｅｎｔｉｇｅｎ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 操作されたｔ細胞を用いて癌を処置するための方法
JP2018527403A (ja) 2015-09-15 2018-09-20 カンステム バイオテック カンパニー リミテッド Ｓｏｄ３を過剰発現する幹細胞を有効成分として含む炎症性疾患の予防又は治療用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
BRPI1015179A2 (pt) * 2009-06-19 2016-04-19 Merck Patent Gmbh biomarcadores e métodos para a determinação de eficácia de anticorpos anti-egfr em terapia de câncer
CA2859452C (en) * 2012-03-27 2021-12-21 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
LT3242933T (lt) * 2015-01-08 2019-06-25 Apceth Gmbh & Co. Kg Genetiškai modifikuotos mezenchiminės kamieninės ląstelės, ekspresuojančios alfa-1 antitripsiną (aat)

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528566A (ja) 2008-07-21 2011-11-24 コンプジェン リミティッド アンジオポエチン由来ペプチド
JP2011529957A (ja) 2008-08-04 2011-12-15 セレリックス エスエー 間葉系幹細胞の使用
JP2014533961A (ja) 2011-11-24 2014-12-18 フンダシオ インスティトゥート ディンベスティガシオ ビオメディカ デ ベルビテージ（イディベル） 改変された幹細胞およびその治療的な使用
JP2016537416A (ja) 2013-11-01 2016-12-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 脳マラリアを治療するためのアンギオポエチンに基づいた介入
JP2017502690A (ja) 2013-12-20 2017-01-26 ノバルティス アーゲー 調節可能キメラ抗原受容体
JP2017520583A (ja) 2014-06-30 2017-07-27 ティジェニクス エス．エー．ユー． 全身性炎症反応症候群の治療のための間葉系間質細胞
JP2018521122A (ja) 2015-06-12 2018-08-02 レンティジェン・テクノロジー・インコーポレイテッドＬｅｎｔｉｇｅｎ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 操作されたｔ細胞を用いて癌を処置するための方法
JP2018527403A (ja) 2015-09-15 2018-09-20 カンステム バイオテック カンパニー リミテッド Ｓｏｄ３を過剰発現する幹細胞を有効成分として含む炎症性疾患の予防又は治療用組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mei, S. H. J., et al.，Prevention of LPS-Induced Acute Lung Injury in Mice by Mesenchymal Stem Cells Overexpressing Angiopoietin 1，PLoS Medicine，4(9): e269，2007年09月04日，p. 1525-1537，doi:10.1371/journal.pmed.0040269

Also Published As

Publication number Publication date
WO2020087160A1 (en) 2020-05-07
JP2022513379A (ja) 2022-02-07
AU2019370629A1 (en) 2021-05-20
EP3874029A1 (en) 2021-09-08
IL282820A (en) 2021-06-30
CN113166729A (zh) 2021-07-23
SG11202103509RA (en) 2021-05-28
US20220010281A1 (en) 2022-01-13
EP3874029A4 (en) 2022-08-03
EP3874029B1 (en) 2023-08-30
CA3116196A1 (en) 2020-05-07
KR20210086662A (ko) 2021-07-08
ES2962812T3 (es) 2024-03-21

Similar Documents

Publication Publication Date Title
KR101992807B1 (ko) 조직 재생을 유도하기 위한 펩티드 및 그의 이용
AU2022204193A1 (en) Methods and compositions for mobilizing stem cells
JP7198823B2 (ja) 全身においてタンパク質を発現させるためのプラットフォームとしての遺伝子工学操作された造血幹細胞
WO2006076288A2 (en) Dna constructs for long-term expression of intravascularly injected naked dna
US20210317411A1 (en) Compositions and methods for haematopoietic stem cell transplantation
EP4010361A1 (en) Methods and compositions for reconstituting microglia
EP3874029B1 (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
CA3116196C (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
HK40057211B (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
HK40057211A (en) Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
US20230414668A1 (en) Cell-based therapy for viral diseases
US20030148952A1 (en) Methods and materials for the recruitment of endothelial cells
JP2025530652A (ja) 遺伝子治療
CN121517527A (zh) 工程化补体因子h相关蛋白及其应用
Gabay et al. Interleukin-18 and interleukin-18 binding protein balance: focus on IL-18BP production and IL-18 maturation in macrophage activation syndrome
Thawer The role of pulmonary innate and adaptive immune responses to helminth infection
JPWO2000008056A1 (ja) 新規なポリペプチド、そのポリペプチドをコードするｃＤＮＡ、およびその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231020

R150 Certificate of patent or registration of utility model

Ref document number: 7372982

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150